secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2024-09-27T23:59:59+00:00
Accession:  0001437749-24-030118
Event type: regulatory
Sentiment:  neutral
Materiality: 0.80
Item codes: 7.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences settles SEC probe for $40M; DOJ not expected to charge company
-------------------------------------------------------------------------------

- Agreed to pay $40M civil penalty without admitting or denying SEC allegations of negligence-based disclosure violations.
- Resolution covers statements about 2020 Phase 2b simufilam trial; DOJ Criminal Division not expected to bring charges.
- Rick Barry appointed Executive Chairman (July 17) and CEO (Sept 6) as part of governance enhancements.
- Net cash use H2 2024 estimated $80-90M including penalty; year-end cash projected $117-127M.
- Settlement subject to U.S. District Court approval; company had previously reserved $40M loss contingency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000143774924030118/0001437749-24-030118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000143774924030118/sava20240927_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-030118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer